Answers are grounded in this paper and cite their sources.
Recent analytical and clinical validation of the Afirma Xpression Atlas (XA) demonstrates test reliability and the identification of genomic alterations that may inform patient management. The updated Afirma Genomic Sequencing Classifier and XA reports aim to optimize the understanding of these contributions, including decisions about observation versus surgery, the need for disease‐specific preoperative testing, associated neoplasm types, prognostics, the identification of molecular targets for systemic therapy, and the recognition of potential hereditary syndromes.
No takes yet. Share an insight, caveat, or question.
Krane et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: